Tekmira Pharmaceuticals is planning to resume its Phase I study of an investigational treatment for Ebola

  • Ebola,FDA,Tekmira,RNAi

Canadian biotech Tekmira Pharmaceuticals ($TKMR) is planning to resume its Phase I study of an investigational treatment for Ebola now that the FDA has waved off some lingering safety concerns.

The agency had effectively halted development of TKM-Ebola, an RNAi therapy, back in July over concerns that it might be unsafe for administration in healthy volunteers. The FDA loosened its hold on the drug in August to allow for dosing of patients with suspected or confirmed Ebola, but the treatment's broader Phase I program remained on ice.

Now, regulators have again modified their clinical hold to allow Tekmira to dose healthy volunteers with as much as 0.24 milligrams of TKM-Ebola per kilogram per day, and the company is planning to get its Phase I safety trial back up and running in the coming weeks. In the study, patients will get either TKM-Ebola or placebo for up to 7 days, and Tekmira expects to have safety data in hand in the second half of this year.

Tekmira's shares have soared and plummeted along with TKM-Ebola's up-and-down development over the past year, fueled by the now-subsided outbreak of the virus in West Africa. July's clinical hold sent the biotech down more than 20%, while the FDA's gradual thawing helped it ascend to an all-time high in October as investors rallied around the drug's potential. But the simultaneous improvement of conditions in Africa have dampened enthusiasm for Ebola treatments, and Friday's news sent the biotech's shares up just 2%.

Meanwhile, the waning numbers of Ebola cases are making it difficult for global outreach organizations and pharma organizations to complete trials for new treatments and vaccines for the virus. Companies including Johnson & Johnson ($JNJ), GlaxoSmithKline ($GSK) and Merck ($MRK) are working with health authorities to study potential cures in Africa, and declining rates of infection--while unquestionably good for the continent--are making enrollment difficult.

Tekmira is developing its Ebola treatment under a $140 million contract with the U.S. Department of Defense. Beyond TKM-Ebola, the company's pipeline is largely focused on hepatitis B, for which it has 8 candidates in various stages of early development. Tekmira's RNAi platform also includes potential treatments for cancer and metabolic disease.


This link:http://www.chemcd.com/news/12986.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.